NARS2 Antibody

Code CSB-PA856950LA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human placenta tissue using CSB-PA856950LA01HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human colon cancer using CSB-PA856950LA01HU at dilution of 1:100

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) NARS2 Polyclonal antibody
Uniprot No.
Target Names
NARS2
Alternative Names
NARS2 antibody; Probable asparagine--tRNA ligase antibody; mitochondrial antibody; EC 6.1.1.22 antibody; Asparaginyl-tRNA synthetase antibody; AsnRS antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Probable asparagine--tRNA ligase, mitochondrial protein (15-210AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The NARS2 Antibody (Product code: CSB-PA856950LA01HU) is Non-conjugated. For NARS2 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA856950LB01HU NARS2 Antibody, HRP conjugated ELISA
FITC CSB-PA856950LC01HU NARS2 Antibody, FITC conjugated
Biotin CSB-PA856950LD01HU NARS2 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, IHC
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Gene References into Functions
  1. NARS2 expression is reduced in AD brain tissue compared with controls. NARS2 expression in brain is associated with GAB2 AD risk variant rs2373115. PMID: 30088171
  2. The individuals with PARS2 and NARS2 mutations demonstrate similar neurological features as those previously reported, with diversity in clinical presentation such as hearing loss and seizure type. PMID: 28077841
  3. Genome-wide SNP analysis identified multiple suggestive novel loci and two of them were also significant in gene-based analysis (CCDC85C and NARS2) that survived after controlling for false-discovery rate at 0.05. PMID: 25649651
  4. In these cells we show that a decrease in oxygen consumption rates (OCR) and electron transport chain (ETC) activity can be rescued by overexpression of wild type NARS2 PMID: 25807530
  5. A variant in NARS2 results in a combined OXPHOS complex deficiency involving complex I and IV, making NARS2 a new member of disease-associated aminoacyl-tRNA synthetases. PMID: 25385316

Show More

Hide All

Involvement in disease
Combined oxidative phosphorylation deficiency 24 (COXPD24); Leigh syndrome (LS)
Subcellular Location
Mitochondrion matrix. Mitochondrion.
Protein Families
Class-II aminoacyl-tRNA synthetase family
Database Links

HGNC: 26274

OMIM: 256000

KEGG: hsa:79731

STRING: 9606.ENSP00000281038

UniGene: Hs.503389

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*